Neurogene
Craig Hebel has extensive experience in the biotechnology and pharmaceutical industry. Craig currently serves as the Head of Manufacturing at Neurogene Inc., a position they have held since August 2019. Prior to this role, they worked at Lonza for nine years, starting in September 2010 as the Head of Viral Vector Operations.
Before joining Lonza, they held various positions in the industry. Craig was the Vice President of Production at Vivante GMP Solutions, Inc. from October 2009 to September 2010. Craig also served as the Director of Manufacturing at ThromboVision Inc. from January 2009 to October 2009, and as the Director of Production Operations at Introgen Therapeutics, Inc. from January 2008 to November 2008.
Craig began their career at Tanox, Inc. in 1992, where they worked for 15 years as the Associate Director of Manufacturing until December 2007. In addition, they briefly held the position of Associate Director of Manufacturing at Genentech from January 2007 to December 2007.
Overall, Craig Hebel has demonstrated their expertise in manufacturing, production operations, and viral vector operations throughout their career in the biotechnology and pharmaceutical industry.
Craig Hebel attended Texas A&M University from 1985 to 1990. No specific degree or field of study was mentioned.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.